

Astrazeneca COVID-19 Vaccine (AZD1222)

- Vaccination protects people from becoming ill with COVID-19.
- AstraZeneca COVID-19 Vaccine demonstrated high efficacy in clinical trials conducted in the United Kingdom and the United States, and is very effective in real world rollouts in preventing severe illness, hospitalisation and death.
- AstraZeneca vaccine is approved by the National Pharmaceutical Regulatory Agency (NPRA) as a safe and effective vaccine against COVID-19 infection for adults 18 years and above.
- Common side effects include pain or tenderness at the injection site, tiredness, headache, muscle pain, and fever and chills (usually for 24 to 48 hours).
- An extremely rare possible side effect is thrombosis with thrombocytopenia syndrome (TTS), where 9.3 cases per million doses have been reported.
- No specific risk factors have been confirmed for TTS. Available data suggest more cases in adults under 60 years of age compared to older adults, and in women compared to men.

Seek medical attention immediately if you experience

1. A severe persistent headache that:
 - does not improve with simple painkillers
 - gets worse when lying down or accompanied by nausea and vomiting
2. Neurological symptoms such as:
 - blurred vision
 - difficulty with speech
 - drowsiness
 - seizures
3. Shortness of breath or chest pain
4. Swelling of the legs
5. Persistent abdominal pain
6. Tiny blood spots under the skin



Monitor signs and symptoms between 4 to 30 days after vaccination. Please refer to the AstraZeneca Clinical Guidance for COVID-19 Vaccination (Malaysia).

The benefits of vaccination greatly outweigh the risks in this situation. If you have any concerns or questions, you can discuss with your doctor before you receive the vaccine.

Information on the AstraZeneca vaccine

1. [Vaxzevria \(previously COVID-19 Vaccine AstraZeneca\)](#)
2. [The Oxford/AstraZeneca COVID-19 vaccine: what you need to know](#)
3. [Interim recommendations for use of the ChAdOx1-S \[recombinant\] vaccine against COVID-19 \(AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience\)](#)
4. [Statement of the Strategic Advisory Group of Experts \(SAGE\) on Immunization: Continued review of emerging evidence on AstraZeneca COVID-19 Vaccines](#)
5. [Global Advisory Committee on Vaccine Safety \(GACVS\) review of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19 Vaccine \(Vaxzevria and Covishield\)](#)
6. [AstraZeneca COVID-19 vaccine: review of very rare cases of unusual blood clots continues](#)

vaksincovid.gov.my

**LINDUNG DIRI,
LINDUNG SEMUA.**



**SPECIAL COMMITTEE ON ENSURING ACCESS
TO COVID-19 VACCINE SUPPLY (JKJAV)**

Vaksin COVID-19 AstraZeneca (AZD1222)

- Vaksinasi melindungi seseorang daripada jatuh sakit kerana COVID-19.
- Vaksin COVID-19 AstraZeneca menunjukkan keberkesanan yang tinggi dalam ujian klinikal di United Kingdom dan Amerika Syarikat, dan amat berkesan untuk digunakan bagi mencegah penyakit yang teruk, kemasukan ke hospital dan kematian.
- Vaksin AstraZeneca telah diluluskan oleh Agensi Regulatori Farmasi Negara sebagai satu vaksin yang selamat dan berkesan terhadap jangkitan COVID-19 bagi orang dewasa berumur 18 tahun dan ke atas.
- Kesan sampingan biasa adalah termasuk sakit atau sengal di tempat suntikan, keletihan, sakit kepala, sakit otot serta demam dan rasa seram sejuk (kebiasaannya selama 24 hingga 48 jam).
- Kemungkinan kesan sampingan yang sangat jarang berlaku adalah dikenali sebagai sindrom trombotik dengan sindrom trombositopenia (TTS) di mana 9.3 daripada satu juta dos telah dilaporkan.
- Tidak ada faktor risiko spesifik yang disahkan untuk TTS. Data yang ada menunjukkan lebih banyak kes dilaporkan pada orang dewasa di bawah 60 tahun berbanding orang dewasa yang lebih tua, dan pada wanita berbanding lelaki.

Dapatkan rawatan dengan segera sekiranya anda mengalami

1. Sakit kepala berterusan yang teruk di mana ia:
 - tidak sembuh dengan ubat penahan sakit biasa
 - bertambah teruk ketika berbaring atau turut merasa loya dan muntah
2. Gejala neurologi seperti:
 - penglihatan kabur
 - kesukaran bertutur
 - merasa pening-pening
 - sawan
3. Sesak nafas atau sakit dada
4. Bengkak kaki
5. Sakit perut yang berterusan
6. Tompokan darah kecil di bawah kulit



Pantau tanda dan gejala antara 4 hingga 30 hari selepas vaksinasi. Sila rujuk Panduan Klinikal Vaksinasi COVID-19 (Malaysia) AstraZeneca.

Dalam situasi ini, manfaat vaksinasi adalah jauh melebihi risiko vaksinasi. Sekiranya anda mempunyai masalah atau pertanyaan, anda boleh berbincang dengan doktor sebelum anda menerima suntikan vaksin.

Maklumat tentang vaksin AstraZeneca

1. [Vaxzevria \(sebelum ini dikenali sebagai Vaksin COVID-19 AstraZeneca\)](#)
2. [Vaksin COVID-19 Oxford/AstraZeneca: apa yang perlu anda tahu](#)
3. [Syor interim bagi penggunaan \[rekombinan\] ChAdOx1-S vaksin terhadap COVID-19 \(Vaksin AZD1222 COVID-19 AstraZeneca, SII Covishield, SK Bioscience\)](#)
4. [Kenyataan Kumpulan Pakar Penasihat Strategik \(SAGE\) mengenai Imunisasi: Semakan berterusan berkenaan bukti terbaru mengenai Vaksin COVID-19 AstraZeneca](#)
5. [Semakan Jawatankuasa Penasihat Global mengenai Keselamatan Vaksin \(GACVS\) mengenai bukti terkini kejadian pembekuan darah yang jarang berlaku dengan Vaksin COVID-19 AstraZeneca \(Vaxzevria dan Covishield\)](#)
6. [Vaksin COVID-19 AstraZeneca: semakan kes-kes yang jarang berlaku berkenaan pembekuan darah luar biasa diteruskan](#)

vaksinovid.gov.my

**LINDUNG DIRI,
LINDUNG SEMUA.**



**JAWATANKUASA KHAS JAMINAN AKSES
BEKALAN VAKSIN COVID-19 (JKJAV)**